FocalTherics (NASDAQ:FOCL) Stock Rating Lowered by Wall Street Zen

Posted by Geri Gentry on Aug 17th, 2026

FocalTherics (NASDAQ:FOCL – Get Free Report) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

A number of other brokerages have also commented on FOCL. Piper Sandler reissued a “neutral” rating and issued a $4.00 price target on shares of FocalTherics in a report on Friday. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of FocalTherics in a research note on Tuesday, June 2nd. Finally, Mizuho set a $15.00 price target on FocalTherics and gave the stock an “outperform” rating in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $7.75.

View Our Latest Analysis on FOCL

FocalTherics Price Performance

Shares of NASDAQ FOCL opened at $4.76 on Friday. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.34 and a quick ratio of 0.99. The stock has a market cap of $178.40 million, a PE ratio of -4.62 and a beta of -0.04. FocalTherics has a one year low of $1.30 and a one year high of $6.40. The company’s fifty day moving average price is $5.39.

FocalTherics (NASDAQ:FOCL – Get Free Report) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.19). The business had revenue of $13.20 million during the quarter. FocalTherics had a negative return on equity of 175.45% and a negative net margin of 56.26%. As a group, equities analysts expect that FocalTherics will post -0.78 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in FOCL. Flax Pond Capital LLC purchased a new stake in FocalTherics during the 4th quarter valued at $2,623,000. Leonteq Securities AG purchased a new position in shares of FocalTherics in the 4th quarter worth $313,000. Rock Springs Capital Management LP boosted its stake in shares of FocalTherics by 7.1% in the 1st quarter. Rock Springs Capital Management LP now owns 1,378,000 shares of the company’s stock worth $5,126,000 after buying an additional 91,500 shares during the last quarter. Kovack Advisors Inc. purchased a new position in shares of FocalTherics in the 4th quarter worth $53,000. Finally, Lido Advisors LLC bought a new stake in shares of FocalTherics in the first quarter worth $40,000. Institutional investors own 62.74% of the company’s stock.

FocalTherics Company Profile

(Get Free Report)

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.